# 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

> **NCT00433927** · PHASE3 · UNKNOWN · sponsor: **PD Dr. med. Volker Heinemann** · enrollment: 568 (estimated)

## Conditions studied

- Neoplasm Metastasis
- Colorectal Cancer

## Interventions

- **DRUG:** 5-FU
- **DRUG:** folinic acid
- **DRUG:** irinotecan
- **DRUG:** cetuximab
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00433927
- **Lead sponsor:** PD Dr. med. Volker Heinemann
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-01
- **Primary completion:** 2014-04
- **Final completion:** 2016-12
- **Target enrollment:** 568 (ESTIMATED)
- **Last updated:** 2014-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433927, "5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00433927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*